Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
2.530
+0.050 (2.02%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Company Description
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases.
Its investigational product, certepetide, is in Phase 2 clinical studies for the treatment of solid tumor, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, colon cancer and glioblastoma multiforme, in combination with a range of anti-cancer regimens.
Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Lisata Therapeutics, Inc.
| Country | United States |
| Founded | 1980 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | David Mazzo |
Contact Details
Address: 110 Allen Road, 2nd Floor Basking Ridge, New Jersey 07920 United States | |
| Phone | 908 842 0100 |
| Website | lisata.com |
Stock Details
| Ticker Symbol | LSTA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000320017 |
| CUSIP Number | 128058302 |
| ISIN Number | US1280583022 |
| Employer ID | 22-2343568 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Kristen K. Buck M.D. | Executive Vice President of Research & Development and Chief Medical Officer |
| James Nisco | Senior Vice President of Finance, Treasurer, CAO and Principal Financial and Accounting Officer |
| Tariq Imam | Senior Vice President of Business Development and Operations and General Counsel |
| Gregory S. Berkin | Chief Information and Data Protection Officer |
| John D. Menditto | Vice President of Investor Relations and Corporate Communications |
| Dr. William K. Sietsema Ph.D. | Vice President of Global Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Jan 23, 2025 | 8-K | Current Report |
| Dec 3, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Aug 21, 2024 | 424B5 | Filing |
| Aug 12, 2024 | 10-Q | Quarterly Report |